BIIB News and Press, Biogen Inc. From 06/05/24

2024-06-05 13:10:12 ET More on Biogen, Eli Lilly, etc. Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Alphabet taps...

2024-06-05 11:52:26 ET Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's dis...

New York, New York--(Newsfile Corp. - June 4, 2024) - Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (NASDAQ: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by...

NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...

Upcoming community events will inform plans to create more equitable flying experiences for passengers with reduced mobility CAMBRIDGE, Mass. and ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Delta Flight Products (DFP), a wholly-owned subsidiary of Delta A...

2024-05-31 16:11:42 ET Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $...

New York, New York--(Newsfile Corp. - May 31, 2024) - Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (NASDAQ: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by...

SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1 QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases w...

2024-05-30 12:24:45 ET Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patient...

Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)? Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive? Did you lose money in your investment in Biogen Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / May 30, 2...